09:18:01 EDT Tue 16 Jul 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Q:NBIX - NEUROCRINE BIOSCIENCES INC - http://WWW.NEUROCRINE.COM
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NBIX - Q0.9146.46·149.990.1147.46    149.0055  94.675Jul 15Jul 1115 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-07-11 16:01U:NBIXNews ReleaseNeurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results
2024-07-01 07:30U:NBIXNews ReleaseNeurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH
2024-06-03 08:01U:NBIXNews ReleaseNeurocrine Biosciences Presented CAHtalyst(TM) Phase 3 Pediatric and Adult Studies, CAHtalog(TM) Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024
2024-06-03 07:35U:NBIXNews ReleaseNeurocrine Biosciences Announces Publication of Primary CAHtalyst(TM) Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
2024-06-03 07:30U:NBIXNews ReleaseNeurocrine Biosciences Announces Publication of Primary CAHtalyst(TM) Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
2024-05-29 16:01U:NBIXNews ReleaseNeurocrine Biosciences to Participate at Investor Conferences in June
2024-05-28 16:14U:NBIXNews ReleaseNeurocrine Biosciences Announces CEO Succession Plan
2024-05-28 08:30U:NBIXNews ReleaseNeurocrine Biosciences to Present New Phase 3 CAHtalyst(TM) Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024
2024-05-21 16:05U:NBIXNews ReleaseNeurocrine Biosciences Announces Publication of Phase 3 KINECT(TM)-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA(TM) (valbenazine) Capsules
2024-05-14 08:30U:NBIXNews ReleaseNeurocrine Biosciences Presented Baseline Data from the CAHtalyst(TM) Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
2024-05-09 09:45U:NBIXNews ReleaseNeurocrine Biosciences Presents CAHtalyst(TM) Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024
2024-05-09 08:30U:NBIXNews ReleaseNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults
2024-05-08 08:30U:NBIXNews ReleaseNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
2024-05-07 16:15U:NBIXNews ReleaseNeurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference
2024-05-07 08:30U:NBIXNews ReleaseNeurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst(TM) Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024
2024-05-06 08:30U:NBIXNews ReleaseNeurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring
2024-05-03 13:15U:NBIXNews ReleaseNeurocrine Biosciences Presented CAHtalyst(TM) Pediatric Study Baseline Characteristics and CAHtalog(TM) Registry Data at PES 2024
2024-05-01 07:00U:NBIXNews ReleaseNeurocrine Biosciences Reports First Quarter 2024 Financial Results
2024-04-30 17:12U:NBIXNews ReleaseNeurocrine Biosciences Announces U.S. FDA Approval of INGREZZA(TM) SPRINKLE (valbenazine) Capsules
2024-04-24 08:30U:NBIXNews ReleaseNeurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community